| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer †
|
O'Shaughnessy, J.
|
|
|
27 |
1 |
p. 106-113
|
artikel
|
| 2 |
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy
|
Grellety, T.
|
|
|
27 |
1 |
p. 199-200
|
artikel
|
| 3 |
Annals of oncology in 2015: the year in review
|
Soria, J.-C.
|
|
|
27 |
1 |
p. 8-9
|
artikel
|
| 4 |
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers †
|
Li, B.T.
|
|
|
27 |
1 |
p. 154-159
|
artikel
|
| 5 |
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial
|
Hagman, H.
|
|
|
27 |
1 |
p. 140-147
|
artikel
|
| 6 |
A rational approach for salvage of testicular cancer patients
|
Selle, F.
|
|
|
27 |
1 |
p. 202
|
artikel
|
| 7 |
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
|
Ilie, M.
|
|
|
27 |
1 |
p. 147-153
|
artikel
|
| 8 |
Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer
|
Kuboki, Y.
|
|
|
27 |
1 |
p. 127-133
|
artikel
|
| 9 |
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma
|
Gupta, M.
|
|
|
27 |
1 |
p. 165-172
|
artikel
|
| 10 |
Correction to: Planning and reporting of quality-of-life outcomes in cancer trials
|
Schandelmaier, S.
|
|
|
27 |
1 |
p. 209
|
artikel
|
| 11 |
Correction to: Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium
|
Waterhouse, M.
|
|
|
27 |
1 |
p. 208
|
artikel
|
| 12 |
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study †
|
Tewari, K.S.
|
|
|
27 |
1 |
p. 114-121
|
artikel
|
| 13 |
Early market access of cancer drugs in the EU
|
Martinalbo, J.
|
|
|
27 |
1 |
p. 96-105
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
27 |
1 |
p. ii-iii
|
artikel
|
| 15 |
Enzalutamide and sleep apnea: an emerging central nervous system side-effect?
|
Labrize, F.
|
|
|
27 |
1 |
p. 206
|
artikel
|
| 16 |
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up †
|
Colombo, N.
|
|
|
27 |
1 |
p. 16-41
|
artikel
|
| 17 |
Fruits, vegetables and lung cancer risk: a systematic review and meta-analysis
|
Vieira, A.R.
|
|
|
27 |
1 |
p. 81-96
|
artikel
|
| 18 |
How much evidence isn't in evidence-based guidelines?
|
Johnson, M.J.
|
|
|
27 |
1 |
p. 205
|
artikel
|
| 19 |
Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?
|
Louis, E.
|
|
|
27 |
1 |
p. 178-184
|
artikel
|
| 20 |
More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysis
|
Basso, U.
|
|
|
27 |
1 |
p. 202-203
|
artikel
|
| 21 |
PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy
|
Goldmann, T.
|
|
|
27 |
1 |
p. 206-207
|
artikel
|
| 22 |
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
|
Bridgewater, J.
|
|
|
27 |
1 |
p. 134-140
|
artikel
|
| 23 |
Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis
|
Veronese, N.
|
|
|
27 |
1 |
p. 42-48
|
artikel
|
| 24 |
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
|
Takeuchi, K.
|
|
|
27 |
1 |
p. 185-192
|
artikel
|
| 25 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02) †
|
Aparicio, T.
|
|
|
27 |
1 |
p. 121-127
|
artikel
|
| 26 |
Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
|
Cherny, N.I.
|
|
|
27 |
1 |
p. 205-207
|
artikel
|
| 27 |
Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis
|
Leoncini, E.
|
|
|
27 |
1 |
p. 68-81
|
artikel
|
| 28 |
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
|
Raggi, D.
|
|
|
27 |
1 |
p. 49-61
|
artikel
|
| 29 |
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
|
Komrokji, R.S.
|
|
|
27 |
1 |
p. 62-68
|
artikel
|
| 30 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial †
|
Weinstein, C.
|
|
|
27 |
1 |
p. 172-178
|
artikel
|
| 31 |
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer
|
Korn, E.L.
|
|
|
27 |
1 |
p. 10-15
|
artikel
|
| 32 |
Table of Contents
|
|
|
|
27 |
1 |
p. iv-vi
|
artikel
|
| 33 |
thanks to referees 2015
|
|
|
|
27 |
1 |
p. 1-5
|
artikel
|
| 34 |
The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine
|
Curigliano, G.
|
|
|
27 |
1 |
p. 6-8
|
artikel
|
| 35 |
The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members
|
Maillet, D.
|
|
|
27 |
1 |
p. 192-198
|
artikel
|
| 36 |
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
|
Wagstaff, J.
|
|
|
27 |
1 |
p. 159-165
|
artikel
|
| 37 |
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinib
|
Haratani, K.
|
|
|
27 |
1 |
p. 200-202
|
artikel
|
Tijdschrift beschrijving